Oral Glucose for Choroiditis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how oral glucose (sugar) intake might affect the thickness of the choroid, a part of the eye. The goal is to gain insights into eye health and the role of sugar intake. Suitable candidates for this trial do not have diabetes or pre-diabetes and do not require significant vision correction, such as glasses stronger than 6 diopters. As an unphased trial, this study provides a unique opportunity to contribute to foundational research on eye health and sugar intake.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that oral glucose is safe for choroiditis?
Studies have shown that oral glucose is generally safe for consumption. It is a common sugar found in many foods and drinks. Although specific safety information about using oral glucose for choroiditis (an eye condition) is lacking, most people tolerate glucose well when taken in normal amounts.
In other contexts, glucose is used without major safety concerns, and serious side effects are rare. This makes it a low-risk option for exploration in research settings. Participants should consult a healthcare provider with any concerns or questions about joining a trial involving glucose.12345Why are researchers excited about this trial?
Unlike the standard treatments for choroiditis, which often involve corticosteroids or immunosuppressants, oral glucose is being explored as a novel approach. Researchers are excited about this treatment because it uses a simple, widely available substance—glucose—in a new way that may have fewer side effects than current medications. Oral glucose could potentially modulate inflammation in the eye without the complications associated with long-term steroid use, offering a gentler alternative for managing this condition.
What evidence suggests that oral glucose might be an effective treatment for choroiditis?
Research has shown that oral glucose intake might affect eye health, particularly in conditions like diabetic retinopathy. A recent study demonstrated a 27% decrease in diabetic eye disease outcomes with oral treatments, suggesting a positive impact on the eyes. While specific data on glucose and choroiditis is lacking, understanding its effects on similar eye conditions could be beneficial. This trial will specifically investigate the effects of oral glucose on choroiditis, aiming to explore how sugar intake might alter the thickness of the choroid, potentially offering new insights into managing eye health.678910
Are You a Good Fit for This Trial?
This trial is for individuals with healthy eyesight, having less than 6 diopters of spherical equivalent refractive error and no diabetes or pre-diabetes. It's not suitable for those with retinal problems or other systemic/ocular conditions that could affect the study results.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants consume 30 grams of sugar and undergo repeated macular OCT scans every 30 minutes for 3 hours
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Oral glucose
Trial Overview
The study examines how taking a dose of oral glucose—a type of sugar—can affect the thickness of the choroid, which is a layer in the back part of your eye.
How Is the Trial Designed?
1
Treatment groups
Active Control
Subjects receive 30g of oral glucose
Find a Clinic Near You
Who Is Running the Clinical Trial?
Southern College of Optometry
Lead Sponsor
Citations
Retrospective Medical Record Review to Describe Use of ...
After RCI therapy, physicians reported improvement for most patients (84%) in response to the question “what is the patient's current status?”; physicians ...
Comparative efficacy of treatments for chronic central ...
Three treatment options provide significant improvement over no treatment: half-dose/-fluence PDT, conventional laser and to a much lesser degree SRT.
Central serous chorioretinopathy: Towards an evidence ...
Two studies examined the effects of oral ketoconazole (200 or 600 mg/day for 4 weeks) in 15 patients with aCSC and 5 patients with cCSC (Golshahi et al ...
RWC Update: Oral Therapy Options for Diabetic Retinopathy ...
2 Most recently, the Phase 4 LENS trial in Scotland reported an approximately 27% relative reduction in composite diabetic eye disease outcomes ...
5.
researchgate.net
researchgate.net/publication/45583442_Punctate_Inner_Choroidopathy_Clinical_Features_and_OutcomesPunctate Inner Choroidopathy Clinical Features and ...
Overall, 40 eyes with PIC-related choroidal neovascular membrane (26%) had final visual acuity less than 6/60. No differences were observed ...
A new small molecule DHODH-inhibitor [KIO-100 (PP-001 ...
For safety reasons the minimum time interval between injection of patients was 7 days to ensure sufficient time for development of adverse ...
Clinical Review
For other safety data, I reviewed the Applicants safety data in the CSR and conducted my own analyses from the datasets when appropriate ...
Ocular Effects of GLP-1 Receptor Agonists
Specifically, among patients with type 2 diabetes, semaglutide users had a hazard ratio (HR) of 4.28 (95% CI 1.62–11.29) for NAION compared to matched controls.
Management of uveitic and chorioretinal conditions in ...
While safety data are limited, analyses from global safety databases have not found any increased risk of miscarriage or congenital ...
The GEMINI Study
All participants received oral prednisone or prednisolone to minimize postsurgical inflammation (Supplementary. Data S1); most also received ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.